indazoles has been researched along with Dermatitis Medicamentosa in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azad, NS; Gallagher, D; O'Connor, A; Ohaji, C; Rosner, G; Sartorius-Mergenthaler, S; Shroff, RT; Subbiah, V; Yarchoan, M; Zahurak, ML; Zinner, R | 1 |
| Adjei, AA; Bishop, WR; Carr, D; Chun, P; Cooper, A; Dayananth, P; Deng, Y; Flaherty, KT; Fong, PC; Hwu, WJ; Kirschmeier, P; Long, BJ; Miselis, NR; Moreno, BH; Moschos, SJ; Ramanathan, RK; Ribas, A; Robert, L; Rubin, EH; Rubino, J; Rush, TS; Samatar, AA; Schiller, J; Shapira-Frommer, R; Shipps, GW; Sullivan, RJ; Tawbi, HA; Zhang, D | 1 |
| Beato-Merino, M; Casado-Verrier, B; Delgado-Mucientes, C; Pérez-Santos, S | 1 |
| Epskamp, C; Hamberg, P; Snels, DG; Yo, GL; Zuetenhorst, HJ | 1 |
| Goto, H; Kiyohara, Y; Niwakawa, M; Omodaka, T; Otsuka, M; Yoshikawa, S; Yoshimi, K | 1 |
| Chevreau, C; Cottura, E; Garrido-Stowhas, I; Sibaud, V | 1 |
| Eisen, T; Escudier, B; Izzedine, H; Mulders, P; Pyle, L; Robert, C; Sternberg, CN; Zbinden, S | 1 |
2 review(s) available for indazoles and Dermatitis Medicamentosa
| Article | Year |
|---|---|
[Dermatologic side effects induced by new angiogenesis inhibitors].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Drug Eruptions; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Skin; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
Topics: Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular System; Drug Eruptions; Europe; Everolimus; Evidence-Based Medicine; Gastrointestinal Tract; Humans; Hypothyroidism; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pneumonia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Weight Loss; Wound Healing | 2012 |
1 trial(s) available for indazoles and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Animals; Biological Availability; Cell Line, Tumor; Diarrhea; Dogs; Dose-Response Relationship, Drug; Drug Eruptions; Drug Evaluation, Preclinical; Fatigue; Female; Humans; Indazoles; Male; MAP Kinase Signaling System; Maximum Tolerated Dose; Mice; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nausea; Neoplasm Staging; Neoplasms; Protein Kinase Inhibitors; Pyridines; Pyrrolidines; Rats; Triazoles; Xenograft Model Antitumor Assays; Young Adult | 2018 |
4 other study(ies) available for indazoles and Dermatitis Medicamentosa
| Article | Year |
|---|---|
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Disease Progression; Disease-Free Survival; Drug Eruptions; Exanthema; Female; Humans; Hypertension; Indazoles; Male; MAP Kinase Kinase Kinases; Middle Aged; Protein Kinase Inhibitors; Pyridones; Pyrimidines; Pyrimidinones; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Survival Rate; Thrombocytopenia | 2017 |
Subacute cutaneous lupus erythematosus induced by the new multikinase inhibitor pazopanib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Eruptions; Humans; Indazoles; Kidney Neoplasms; Lupus Erythematosus, Cutaneous; Male; Pyrimidines; Sulfonamides | 2014 |
Bullous fixed drug eruption in a patient with metastatic renal cell carcinoma induced by iodinated contrast during pazopanib treatment.
Topics: Aged; Antineoplastic Agents; Blister; Carcinoma, Renal Cell; Contrast Media; Drug Eruptions; Hand Dermatoses; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Sulfonamides; Tomography, X-Ray Computed; Triiodobenzoic Acids | 2016 |
Case of severe ulceration induced by pazopanib.
Topics: Adolescent; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Drug Eruptions; Fatal Outcome; Female; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides | 2017 |